Abstract 1871
Background
Tamoxifen is essential in the treatment of estrogen receptor positive breast cancer. Concentrations of its active metabolite endoxifen > 5.97 ng/mL have been associated with a 26% lower recurrence rate in the adjuvant setting (Madlensky 2011), providing a rationale for therapeutic drug monitoring. However, the risk of high endoxifen concentrations has not been established. Therefore, we investigated whether extremely high endoxifen levels are correlated with a higher incidence of clinically significant toxicities.
Methods
Patients receiving adjuvant tamoxifen treatment (20 mg) with a steady state endoxifen level above 25 ng/mL were retrospectively identified in databases of the CYPTAM study (n = 667, NTR 1509) and of samples collected in routine care (n = 1768). The percentage of patients with clinically significant toxicities, defined as toxicities leading to either dose reduction or treatment discontinuation, was compared to the overall tamoxifen population. As historical comparison, studies described in the EBCTCG overview (2011) in which patients received adjuvant tamoxifen (20 mg) and which reported clinically significant toxicities were selected.
Results
26 patients (1.5%) had an endoxifen level > 25 ng/mL, of which 4 patients (15%) had clinically significant toxicities, compared to 10.2% in the overall tamoxifen population (p = 0.39, weighed average of 10 clinical trials, n = 9688, Baum (2002), Margolese (2016), Chirgwin (2016), Morales (2007), Bartlett (1987), Colleoni (2006), Bonneterre (2001), Kaufmann (2005), Bramwell (2010), Tevaarwerk (2014)). Reported toxicities were mood disturbances (n = 3), hot flushes (n = 2) and musculoskeletal disorders (n = 1). Median time on treatment was 28 months in patients with high endoxifen levels, compared to 47 months reported in literature.
Conclusions
The incidence of clinically significant toxicities is relatively low and is similar in patients with extremely high endoxifen levels and the overall tamoxifen population. Therefore, dose reductions are not indicated in patients with high endoxifen concentrations without toxicity.
Clinical trial identification
CYPTAM study: NTR 1509 (release date 27 October 2008).
Legal entity responsible for the study
The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital.
Funding
Has not received any funding.
Editorial Acknowledgement
Not applicable
Disclosure
N. van Erp: Research funding (all to the institution): Novartis, Astellas, Janssen-Cilag, AstraZeneca, GSK, Boehringer-Ingelheim, Gilead, Roche, Pfizer, Sanofi. R.H.J. Mathijssen: Research support: Astellas, Bayer, Boehringer Ingelheim, Cristal Therapeutics, Novartis, Pamgene, Pfizer, Roche and Sanofi; Consultation fees: Novartis, Servier; Travel Support: Astellas, Pfizer. N. Steeghs: Research funding (all to the institution): AstraZeneca, Bayer, BMS, Novartis, GSK, Pfizer, Roche, Boerringer Ingelheim, Blueprint. All other authors have declared no conflicts of interest.
Resources from the same session
1959 - Incidence and Survival among Young Women with Stage I-III Breast Cancer
Presenter: Alexandra Thomas
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4740 - Toxicity and Clinical Outcomes of Partial Breast Irradiation (PBI) Compared to Whole Breast Irradiation (WBI) for Early Stage Breast Cancer: A Systematic Review and Meta-analysis
Presenter: Hadar Goldvaser
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2092 - Should anthracyclines always be present in the adjuvant treatment of breast cancer (BC)? A systematic review and meta-analysis of randomized controlled trials (RCTs)
Presenter: Rafael Caparica
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
5886 - Taxane & Cyclophosphamide vs Anthracycline & Taxane combination therapy as adjuvant treatment of breast cancer; a meta-analysis of randomized-controlled trials by the Hellenic Academy of Oncology (E.AK.O.)
Presenter: Panagiotis Ntellas
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2323 - Risk of cardiovascular late effects in breast cancer survivors: a population-based study
Presenter: Jihyoun Lee
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2820 - Diagnostic Value of Contrast Enhanced Digital Mammography versus Contrast Enhanced MRI for Preoperative Evaluation of Breast Cancer
Presenter: Eun Young Kim
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3739 - Relationship between androgen receptor and tumor infiltrating lymphocytes in triple negative breast cancer
Presenter: Luis Felipe Sánchez-Cousido
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4849 - Use of red clover in premenopausal breast cancer patients receiving hormonal adjuvant treatment: biological and clinical implications from a randomized clinical trial
Presenter: Cristina Ferraris
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2788 - PROMs following breast-conserving therapy for breast cancer: results from a prospective longitudinal monocentric study
Presenter: Isabelle Kindts
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4208 - Impact on disease-free survival (DFS) of the surgical waiting time (SWT) for patients (Pts) with early breast cancer (BC)
Presenter: RIKIYA Nakamura
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract